Cleveland Clinic 29th Annual Diabetes Day 2025

Include: 16 videos + 20 pdfs, size: 5.35 GB

Target Audience: endocrinologists, diabetes educators

Information:

The 29th Annual Diabetes Day: Therapeutics, Technology and Surgery is presented by the Cleveland Clinic Department of Endocrinology, Diabetes and Metabolism to provide up-to-date reviews of management strategies and research on the complications of diabetes. Key topic areas that will be addressed include:

• Review of therapeutic options to manage both Type 1 and 2 diabetes and their complications, including a pump update, and new insulins and continuous glucose monitoring updates.
• Importance of maintaining muscle mass during obesity management.
• Latest technology in insulin pumps
• New roles for GLP1 receptor agonists SGLT-2 inhibitors and mineralocorticoid receptor antagonists
• Complications of GLP-1 receptor agonists

This year’s curriculum will also feature discussions about:

• Glucose variability and diabetes
• Effects of high fat and high protein diets on glucose control
• Effects of GLP-1 on sleep apnea
• Nutritional supplements in treatment of DM2

The goal of this symposium is to increase practitioners’ competence and clinical performance in treating diabetes and its complications and, ultimately, to improve patient outcomes.

Attendees will be able to:

• Critically appraise clinical evidence and guidelines supporting hybrid closed-loop systems in pregnancy and identify key considerations when initiating and monitoring hybrid closed-loop pumps during pregnancy.
• Describe the efficacy of inhaled insulin to insulin pump therapy in diabetes management.
• Discuss the role of nutritional supplements in the management of Type 2 diabetes and glycemic control, including the use of berberine.
• Discuss future directions and challenges in developing and implementing oral GLP-1 agonists and multi-agonist therapy in diabetes care and summarize clinical evidence on the incidence and risk of gastroparesis, pancreatitis, and thyroid cancer associated with GLP-1 agonist use.
• Analyze current research and define treatment strategies for challenges in diabetes care, including dementia, blood pressure, including intensive blood pressure control, and cardiovascular and renal complications in diabetes.
• Discuss evidence-based treatment strategies for post-gastric bypass hypoglycemia, including dietary modifications, pharmacotherapy, and other interventions.
• Discuss practical considerations for initiating and titrating novel therapies such as efsitora alfa in different patient populations, including those with complex diabetes management needs.

Who should attend?

This activity is designed for physicians, diabetes educators, nurses, nurse practitioners, pharmacists, pharmacy technicians, physician assistants, residents and fellows, and other health care professionals who care for patients with diabetes.

+ Topics: